Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade

PURPOSE: Adjuvant immunotherapy produces durable benefit for patients with resected melanoma, but many develop recurrence and/or immune-related adverse events (irAE). We investigated whether baseline serum autoantibody (autoAb) signatures predicted recurrence and severe toxicity in patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Johannet, Paul, Liu, Wenke, Fenyo, David, Wind-Rotolo, Megan, Krogsgaard, Michelle, Mehnert, Janice M., Weber, Jeffrey S., Zhong, Judy, Osman, Iman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662924/
https://www.ncbi.nlm.nih.gov/pubmed/36106402
http://dx.doi.org/10.1158/1078-0432.CCR-22-0404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662924/
https://www.ncbi.nlm.nih.gov/pubmed/36106402
http://dx.doi.org/10.1158/1078-0432.CCR-22-0404

Ejemplares similares